research use only
Cat.No.S2325
|
In vitro |
DMSO
: 64 mg/mL
(199.84 mM)
Ethanol : 2 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 320.25 | Formula | C15H10O7 .H2O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 6202-27-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Aurantica | Smiles | C1=CC(=C(C=C1O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O.O | ||
| In vitro |
Morin hydrate is a flavonoid isolated from Maclura pomifera (Osage orange), Maclura tinctoria (old fustic) and from leaves of Psidium guajava (common guava). Morin hydrate as an antioxidant improves the survival time of rat glomerular mesangial cells which are attacked by oxyradicals. Morin is also an effective hepatoprotector, both in cultured cells and in hepatic ischemia-reperfusion. Morin hydrate is a new type of Islet Amyloid Polypeptide (IAPP) inhibitor, which may be used in type-2 diabetes and islet cell transplants.
|
References |
|
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05231018 | Unknown status | COVID-19|Mental Health Impairment|Telemedicine |
Fondazione IRCCS Ca'' Granda Ospedale Maggiore Policlinico |
October 28 2020 | Not Applicable |
| NCT04653155 | Unknown status | Insomnia |
Hospital Authority Hong Kong |
June 1 2020 | Not Applicable |
| NCT04144231 | Recruiting | Insomnia|Schizophrenia|Schizoaffective Disorder |
Helsinki University Central Hospital|University of Helsinki|Finnish Institute for Health and Welfare|Finnish Institute of Occupational Health |
December 19 2019 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.